Bayer AG reported Q4 2024 sales of €11.73 billion, exceeding the estimated €11.37 billion, with an adjusted EBITDA of €2.35 billion and a 20% EBITDA margin, slightly above expectations. However, adjusted EPS fell to €0.28, far below the consensus estimate of €1.00. The company anticipates a third consecutive year of declining profits in 2025 but projects a return to earnings growth in 2026. Challenges include a 4.4% drop in Q4 sales in its Crop Science division, which also saw a 4.3% annual sales decline due to reduced herbicide and fungicide sales and lower commodity prices. Bayer reported a net loss of €335 million for Q4 2024, with FY24 EBITDA dropping 22.3% to €2.35 billion. Bayer's CEO faces mounting investor pressure to deliver on turnaround efforts as the company forecasts FY25 core EPS between €4.50 and €5.00. Despite maintaining its dividend at €0.11 per share, Bayer's shares rose to a four-month high following the announcements.